Intravesical Dimethyl Sulfoxide Inhibits Acute and Chronic Bladder Inflammation in Transgenic Experimental Autoimmune Cystitis Models

Autor: Xiaohong Chen, Karl J. Kreder, Wujiang Liu, Yi Luo, Ronald Kim
Rok vydání: 2011
Předmět:
Pathology
Adoptive cell transfer
Health
Toxicology and Mutagenesis
030232 urology & nephrology
lcsh:Medicine
Epitopes
Mice
chemistry.chemical_compound
0302 clinical medicine
Cystitis
Acute Cystitis
Urinary Bladder Diseases
Interstitial cystitis
General Medicine
Chronic Cystitis
Pathophysiology
3. Good health
030220 oncology & carcinogenesis
Acute Disease
Molecular Medicine
Female
medicine.symptom
Urinary bladder disease
Research Article
Biotechnology
medicine.medical_specialty
Article Subject
lcsh:Biotechnology
Mice
Transgenic
Inflammation
Autoimmune Diseases
03 medical and health sciences
lcsh:TP248.13-248.65
Genetics
medicine
Animals
Dimethyl Sulfoxide
Molecular Biology
Dose-Response Relationship
Drug
business.industry
Dimethyl sulfoxide
lcsh:R
medicine.disease
Disease Models
Animal
chemistry
Chronic Disease
Cancer research
business
Spleen
Zdroj: Journal of Biomedicine and Biotechnology
Journal of Biomedicine and Biotechnology, Vol 2011 (2011)
ISSN: 1110-7251
1110-7243
Popis: New animal models are greatly needed in interstitial cystitis/painful bladder syndrome (IC/PBS) research. We recently developed a novel transgenic cystitis model (URO-OVA mice) that mimics certain key aspects of IC/PBS pathophysiology. This paper aimed to determine whether URO-OVA cystitis model was responsive to intravesical dimethyl sulfoxide (DMSO) and if so identify the mechanisms of DMSO action. URO-OVA mice developed acute cystitis upon adoptive transfer of OVA-specific OT-I splenocytes. Compared to PBS-treated bladders, the bladders treated with 50% DMSO exhibited markedly reduced bladder histopathology and expression of various inflammatory factor mRNAs. Intravesical DMSO treatment also effectively inhibited bladder inflammation in a spontaneous chronic cystitis model (URO-OVA/OT-I mice). Studies further revealed that DMSO could impair effector T cells in a dose-dependent manner in vitro. Taken together, our results suggest that intravesical DMSO improves the bladder histopathology of IC/PBS patients because of its ability to interfere with multiple inflammatory and bladder cell types.
Databáze: OpenAIRE
Externí odkaz: